Efficacy of Mazdutide on Fatty Pancreas

What Was Tested

The trial (not phased) is built around Mazdutide.

The study plans to enroll 194 participants with overweight or obesity, who will be randomly assigned in a 1:1 ratio to either the mazdutide plus standardized lifestyle intervention group or the placebo plus standardized lifestyle intervention group, for a treatment duration of 48 weeks.

It had two arms (groups): Intervention group (experimental) and Control group (placebo comparator).

Standardized lifestyle intervention + mazdutide.

Standardized lifestyle intervention + placebo.

The registry classes the interventions as drug and other.

More on the Plan

Fatty pancreas is a clinicopathological syndrome characterized by fat infiltration in pancreatic tissue.

Among these, excessive fat deposition within pancreatic tissue occurring against the backdrop of metabolic abnormalities is termed metabolic dysfunction-associated fatty pancreas (MAFP), which is commonly seen in individuals with overweight, obesity, or metabolic syndrome.

Although lifestyle intervention serves as the foundational treatment, long-term patient adherence remains limited.

However, no dedicated studies have yet evaluated the impact of mazdutide on pancreatic fat content in obese patients.

Who Took Part

194 planned participants were the target.

It was open to people of any sex aged from 18 years up to 60 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age 18-60 years (inclusive) at screening, regardless of gender;. Fully informed about the study and voluntarily signed written informed consent;. Agreed to maintain a stable lifestyle (including diet and exercise habits) during the study. Abdominal obesity (central obesity): Waist circumference ≥90 cm in men, ≥85 cm in women;. Blood pressure ≥130/85 mmHg, and/or diagnosed hypertension under treatment;.

The full record lists 10 inclusion and 0 exclusion criteria.

How the Study Was Run

Design: randomized, parallel-group and quadruple-blind.

The participants were allocated by chance, so the Mazdutide group and the comparison group should start out alike.

The Mazdutide group and the comparison group ran side by side rather than switching.

Neither the participants nor the staff measuring them knew who was on Mazdutide, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2026-11-15 with completion listed for 2028-06-30.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Percentage change in Intrapancreatic Fat Deposition (IPFD) from baseline (time frame: From baseline to Week 48).

It also tracked 13 secondary outcomes, for example Change in visceral fat area, Change in Body Mass Index (BMI), Change in body weight, Change in waist circumference, Change in basal metabolic rate (BMR) and Changes in complete blood count (CBC) parameters.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Mazdutide in 194 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Mazdutide compound page, all human trials.